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ABSTRACT: Biliary clearance (CLb) is often underestimated by in vitro–in vivo extrapolation
from sandwich-cultured hepatocytes (SCHs). The objective of this study was to compare the
performance of a universal correction factor with transporter-based correction factors in cor-
recting underestimation of CLb. The apparent in vitro CLb of a training set of 21 compounds
was determined using the SCH model and extrapolated to apparent in vivo CLb (CLb, app). A uni-
versal correction factor (10.2) was obtained by a linear regression of the predicted CLb, app and
observed in vivo CLb of training set compounds and applied to an independent test set (n = 20);
the corrected CLb predictions of 13 compounds were within twofold error of observed values.
Furthermore, two transporter-based correction factors (Organic anion transporting polypep-
tides/multidrug-resistance-related protein 2 and diffusion/P-glycoprotein) were estimated by
linear regression analysis of training set compounds. The applications of the two correction fac-
tors to the test set resulted in improved prediction precision. In conclusion, both the universal
correction factor and transporter-based correction factors provided reasonable corrections of
CLb values, which are often underestimated by the SCH model. The use of transporter-based
correction factors resulted in an even greater improvement of predictions for compounds with
intermediate-to-high CLb values. © 2013 Wiley Periodicals, Inc. and the American Pharmacists
Association J Pharm Sci 102:2837–2850, 2013
Keywords: biliary excretion; hepatocytes; clearance; drug transport; hepatobiliary disposi-
tion; in vitro/in vivo correlations (IVIVC); organic aniontransporting polypeptide transporters;
P-glycoprotein
INTRODUCTION
The accurate prediction of hepatic clearance (CLH) is
an essential step in the identification of new chemi-
cal entities as drug candidates and in the estimation
of human pharmacokinetics. CLH is determined by
hepatic metabolism and biliary excretion. Reasonable
prediction accuracy of CLH for compounds with high
hepatic metabolism has been achieved by interspecies
scaling and in vitro–in vivo extrapolation (IVIVE)
from liver microsome or hepatocyte incubations.1,2
By contrast, the quantitative prediction of CLH is
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still very challenging for compounds with low hepatic
metabolism and high biliary excretion.2
In vitro–in vivo extrapolation from sandwich-
cultured hepatocytes (SCHs) is an approach to esti-
mating biliary clearance (CLb); however, low bile or
blood flow and the variable expression levels of in-
flux and/or efflux transporters can result in a 10–100-
fold underestimation of CLb in IVIVE from SCH.3,4
Several reports reveal that the expression levels and
activities of influx transporters such as Oatps, Ntcp,
and Oct1 in rat hepatocytes were consistently and
considerably reduced in the SCH model,5–7 thus lead-
ing to underestimation of CLb. Additionally, the ex-
pression levels of canalicular efflux transporters are
inconsistent between different laboratories. Li et al.8
reported a 40% decrease in the bile salt export pump
(Bsep) protein level, a 50% decrease in the multidrug-
resistance-related protein 2 (Mrp2) protein level, and
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a fivefold increase in the breast cancer resistance
protein (Bcrp) level in sandwich-cultured rat hepato-
cytes (SCRHs) over 5 days in culture. Tchaparian et
al.7 observed dramatically increased protein levels of
P-glycoprotein (P-gp), Bcrp, and Mrp 1, 2, 3, and 4
over 4 days in culture. In Borlak’s report,5 the expres-
sion levels of canalicular transporters P-gp and Mrp2
were similar to those determined in vivo.
One strategy for correcting the underestimation of
CLb is to incorporate a universal empirical correction
factor determined by correlating CLb predicted from
SCRHs with the observed in vivo CLb.9 A reasonable
correlation between CLb predicted by SCRHs and in
vivo CLb was observed among drugs that undergo
similar uptake (Organic anion transporting polypep-
tides, Oatps) and efflux mechanisms (Mrp2 or Bcrp)
such as angiotensin II receptor blockers, 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA)reductase in-
hibitors, and $-lactam antibiotics.9–11 On the contrary,
for compounds in which different combinations of in-
flux and efflux transporters are involved in the bil-
iary excretion, or when passive diffusion is involved,
the universal correction factor might not work. To ad-
dress this issue, Li et al.4 proposed using the ratio of
the protein amount of canalicular efflux transporters
(Mrp2, Bsep, and Bcrp) in rat liver to that in SCRH
as a correction factor. Improved prediction accuracy
was achieved by this method; however, this strategy
ignored the decreased expression levels of sinusoidal
influx transporters in SCRHs, which might seriously
affect the predictability of the SCRH model.
In the current study, a universal correction factor
and a series of correction factors based on the activ-
ities of both influx and efflux transporters were ex-
amined for IVIVE of CLb. A universal correction fac-
tor was estimated by linear regression analysis of 21
compounds in a training set. To determine whether
transporter-specific correction factors can improve
IVIVE, the compounds in the training set were di-
vided into transporter-specific subgroups based on
uptake and excretion mechanisms. Although both
the universal correction factor and the transporter-
specific correction factors provided reasonable CLb
predictions when applied to the independent test set;
the use of transporter-specific correction factors re-
sulted in a greater improvement of prediction preci-
sion.
MATERIALS AND METHODS
Chemicals
Topotecan, benazeprilat, rosuvastatin, rosuvastatin-
d6, candesartan, atorvastatin, olmesartan, defera-
sirox, temocaprilat, irinotecan, and octreotide acetate
were purchased from Toronto Research Chemicals
(North York, Ontario, Canada). Trovafloxacin and
fluvastatin were obtained from Torcris Bioscience
(Ellisville, Missouri) and Cayman Chemical Com-
pany (Ann Arbor, Michigan), respectively. Probenecid
was supplied by Santa Cruz Biotechnology (Santa
Cruz, California). [3H]Taurocholate (5 Ci/mmol; pu-
rity >97%) was purchased from PerkinElmer Life and
Analytical Sciences, Inc. (Waltham, Massachusetts).
All other chemicals were purchased from Sigma–
Aldrich (St. Louis, Missouri).
Metabolic Stability Assay
Cryopreserved rat hepatocytes (Celsis IVT, Balti-
more, Maryland) were used for the hepatocyte stabil-
ity assay. The cryopreserved hepatocytes were thawed
in InVitroGROTM HT (Celsis IVT, Baltimore, Mary-
land) medium and centrifuged at 100g for 10 min.
Cells were resuspended in Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco R©, Grand Island, New York),
and viability was assessed by the trypan blue exclu-
sion method. Hepatocytes with viability greater than
80% were used in the study. The compounds (1:M in
DMEM) were incubated with hepatocytes (0.5 × 106
cells/mL) in a CO2 incubator with 95% air/5% CO2
at 37◦C and 95% humidity. At 0, 10, 30, and 60 min,
aliquots of the incubation mixture were taken out and
the reaction was quenched by adding two volumes
of acetonitrile containing 100 nM of rosuvastatin-d6.
The mixtures were then centrifuged at 2095g for
10 min to precipitate the protein. The supernatants
were diluted with two volumes of water and trans-
ferred into a 96-well assay plate to measure the disap-
pearance of parent compounds by liquid chromatog-
raphy–tandem mass spectrometry (LC–MS/MS). The
predicted hepatic metabolic clearance (CLmet) was
calculated using the following previously reported
equation2:
CLmet = (QP × fu × CLint)/(QP + fu × CLint) (1)
where Qp represents the rat hepatic plasma flow rate
(40 mL*min−1*kg−1), CLint represents the intrinsic
clearance, and fu represents the unbound fraction in
rat plasma, which was collected from the literature
(Table 1).
Hepatocyte Culture
Sandwich-cultured rat hepatocytes (B-CLEAR R©),
which were isolated from male Wistar rats and cul-
tured in 24-well plates, were purchased from Qualyst,
Inc. (Durham, North Carolina). Hepatocytes were cul-
tured in the medium provided by Qualyst, Inc. at
37◦C in a humidified incubator with 95% air/5% CO2.
Medium was changed daily. On day 4 after hepatocyte
seeding, the SCRHs were subjected to accumulation
studies.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 102, NO. 8, AUGUST 2013 DOI 10.1002/jps
IN VITRO–IN VIVO EXTRAPOLATION OF BILIARY CLEARANCE 2839
T
ab
le
1.
T
ra
in
in
g
S
et
(n
=
21
)–
O
bs
er
ve
d
an
d
P
re
di
ct
ed
C
L
b
(E
xt
ra
po
la
te
d
fr
om
C
L
b,
ap
p,
in
vi
tr
o)
C
om
po
u
n
ds
M
aj
or
In
fl
u
x
T
ra
n
sp
or
te
rs
M
aj
or
E
ffl
u
x
T
ra
n
sp
or
te
rs
C
L
′ b
,a
pp
(m
L
*m
in
−1
*k
g−
1
)a
f u
C
L
′ b
,a
pp
×
f u
P
re
di
ct
ed
C
L
b,
ap
p
(E
q.
4)
(m
L
*m
in
−1
*k
g−
1
)
C
L
b
C
or
re
ct
ed
by
×1
0.
2
(m
L
*m
in
−1
*k
g−
1
)
O
bs
er
ve
d
In
V
iv
o
C
L
b
(m
L
*m
in
−1
*k
g−
1
)
C
at
eg
or
y
P
re
di
ct
ed
/
O
bs
er
ve
db
V
in
cr
is
ti
n
e
D
if
fu
si
on
(R
ef
.1
2)
P
-g
p
(R
ef
.1
2)
11
.5
0.
4
(R
ef
.1
3)
4.
61
4.
13
42
.1
33
.1
(R
ef
.1
4)
H
/H
T
au
ro
ch
ol
at
e
N
tc
p
(O
at
ps
)
B
se
p
19
.7
0.
15
(R
ef
.4
)
2.
95
2.
75
28
.0
29
.8
(R
ef
.9
)
H
/H
T
em
oc
ap
ri
la
t
O
at
ps
(R
ef
.1
5)
M
rp
2
(R
ef
.1
6)
45
.7
0.
06
39
(R
ef
.1
7)
2.
92
2.
72
27
.8
34
.4
(R
ef
.1
7)
M
/H
P
ro
be
n
ec
id
O
at
2
(R
ef
.1
8)
(O
at
ps
)
M
rp
2
(R
ef
.1
9)
25
.2
0.
11
6
(R
ef
.2
0)
2.
92
2.
72
27
.8
28
.5
9
(R
ef
.1
9)
M
/H
Ir
in
ot
ec
an
O
at
ps
(R
ef
.2
1)
P
-g
p(
M
rp
2)
(R
ef
s.
22
,2
3)
9.
44
0.
2
(R
ef
.2
4)
1.
89
1.
80
18
.4
20
.6
(R
ef
s.
24
,2
5)
M
/M
E
ry
th
ro
m
yc
in
O
at
2
(R
ef
.2
6)
(O
at
ps
)
(R
ef
.2
7)
P
-g
p
(R
ef
.2
8)
2.
34
0.
78
(R
ef
.2
9)
1.
83
1.
75
17
.8
15
.5
(R
ef
.2
7)
M
/M
R
os
u
va
st
at
in
O
at
ps
(R
ef
.3
0)
B
cr
p
(R
ef
.3
0)
44
.9
0.
03
9
(R
ef
.1
1)
1.
75
1.
68
17
.1
24
.3
(R
ef
.1
1)
M
/M
B
en
az
ep
ri
la
t
O
at
ps
(R
ef
s.
15
,1
7)
M
rp
2
(R
ef
.1
7)
7.
04
0.
24
5
(R
ef
.1
7)
1.
72
1.
65
16
.9
20
.2
(R
ef
.1
7)
M
/M
F
ex
of
en
ad
in
e
O
at
ps
(R
ef
.3
1)
M
rp
2(
B
se
p)
(R
ef
.3
1)
12
.0
0.
11
(R
ef
.3
2)
1.
32
1.
28
13
.0
11
.4
(R
ef
.3
3)
M
/L
C
ol
ch
ic
in
e
D
if
fu
si
on
(R
ef
.3
4)
P
-g
p(
M
rp
2)
(R
ef
s.
35
,3
6)
3.
04
0.
38
9
(R
ef
.3
7)
1.
18
1.
15
11
.7
9.
05
(R
ef
.3
5)
L
/L
T
ro
va
fl
ox
ac
in
N
.A
.
N
.A
.
7.
36
0.
11
(R
ef
.3
8)
0.
81
0
0.
79
4
8.
09
8.
39
(R
ef
.3
8)
L
/L
E
n
al
ap
ri
la
t
O
at
ps
(R
ef
.3
9)
M
rp
2
(R
ef
.3
9)
1.
51
0.
42
(R
ef
.1
7)
0.
63
4
0.
62
4
6.
36
2.
96
(R
ef
.1
7)
L
/L
A
to
rv
as
ta
ti
n
O
at
ps
(R
ef
.4
0)
M
rp
2
(R
ef
.4
0)
9.
76
0.
05
67
(R
ef
.4
1)
0.
55
3
0.
54
6
5.
56
6.
2
(R
ef
.4
2)
L
/L
M
it
ox
an
tr
on
e
D
if
fu
si
on
(R
ef
.4
3)
B
cr
p(
P
-g
p)
(R
ef
s.
43
,4
4)
8.
24
0.
05
(R
ef
.4
5)
0.
41
2
0.
40
8
4.
16
7.
2
(R
ef
.4
6)
L
/L
A
A
F
E
(n
=
14
)
1.
26
L
om
efl
ox
ac
in
N
.A
.
N
.A
.
0.
48
0
0.
72
2
(R
ef
.4
7)
0.
34
7
0.
34
4
3.
50
0.
25
3
(R
ef
.4
7)
L
/L
F
lu
va
st
at
in
O
at
ps
(R
ef
.4
8)
M
rp
2
(R
ef
.4
9)
29
.1
0.
00
98
6
(R
ef
.4
1)
0.
28
7
0.
28
5
2.
91
3.
78
(R
ef
.4
1)
L
/L
In
do
m
et
h
ac
in
O
at
2
(R
ef
.5
0)
P
-g
p
(R
ef
.5
1)
12
0
0.
00
2
(R
ef
.5
2)
0.
24
1
0.
24
0
2.
44
0.
45
(R
ef
.5
3)
L
/L
O
ct
re
ot
id
e
N
.A
.
P
-g
p
(R
ef
.5
4)
0.
30
2
0.
41
(R
ef
.5
5)
0.
12
4
0.
12
4
1.
27
7.
44
(R
ef
.5
6)
L
/L
D
ef
er
as
ir
ox
D
if
fu
si
on
M
rp
2
(R
ef
.5
7)
10
.4
0.
01
(R
ef
.5
8)
0.
10
4
0.
10
4
1.
06
5.
6
(R
ef
.5
7)
L
/L
O
lm
es
ar
ta
n
O
at
ps
(R
ef
.5
9)
M
rp
2
(R
ef
.5
9)
3.
44
0.
01
(R
ef
.1
0)
0.
03
44
0.
03
44
0.
35
1
2.
22
(R
ef
.1
0)
L
/L
C
an
de
sa
rt
an
N
.A
.
N
.A
.
1.
55
0.
00
65
1
(R
ef
.1
7)
0.
01
01
0.
01
01
0.
10
3
3.
03
(R
ef
.1
7)
L
/L
A
A
F
E
of
to
ta
l
tr
ai
n
in
g
se
t
(n
=
21
)
2.
20
a
C
L
′ b
,a
pp
(m
L
/m
in
/k
g)
w
as
de
ri
ve
d
by
sc
al
in
g
in
vi
tr
o
ap
pa
re
n
t
C
L
b
(m
L
*m
in
−1
*m
g−
1
of
pr
ot
ei
n
)
w
it
h
ph
ys
io
lo
gi
ca
lp
ar
am
et
er
s:
20
0
m
g
pr
ot
ei
n
/g
ra
t
li
ve
r
ti
ss
u
e
an
d
40
g
ra
t
li
ve
r
ti
ss
u
e/
kg
bo
dy
w
ei
gh
t.
b
C
L
b
ca
te
go
ri
es
:l
ow
,i
n
vi
vo
C
L
b
≤3
0%
(1
2
m
L
*m
in
−1
*k
g−
1
)
of
li
ve
r
pl
as
m
a
fl
ow
;m
od
er
at
e,
30
%
–7
0%
(1
2–
28
m
L
*m
in
−1
*k
g−
1
)
of
li
ve
r
pl
as
m
a
fl
ow
;a
n
d
h
ig
h
,≥
70
%
(2
8
m
L
*m
in
−1
*k
g−
1
)
of
li
ve
r
pl
as
m
a
fl
ow
. C
om
po
u
n
ds
ar
e
or
de
re
d
ba
se
d
on
pr
ed
ic
te
d
C
L
b,
ap
p
.
P
re
di
ct
io
n
s
ou
ts
id
e
th
e
tw
of
ol
d
er
ro
r
of
ob
se
rv
ed
in
vi
vo
C
L
b
ar
e
h
ig
h
li
gh
te
d
in
bo
ld
.
A
A
F
E
,a
ve
ra
ge
ab
so
lu
te
fo
ld
er
ro
r;
C
L
b
,b
il
ia
ry
cl
ea
ra
n
ce
;C
L
b,
ap
p
,a
pp
ar
en
t
bi
li
ar
y
cl
ea
ra
n
ce
;C
L
′ b
,a
pp
,
ap
pa
re
n
t
bi
li
ar
y
cl
ea
ra
n
ce
sc
al
ed
to
kg
bo
dy
w
ei
gh
t;
f u
,u
n
bo
u
n
d
fr
ac
ti
on
in
pl
as
m
a;
N
.A
.,
n
ot
av
ai
la
bl
e.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 102, NO. 8, AUGUST 2013
2840 ZOU ET AL.
Accumulation Studies and Analysis
Accumulation studies were conducted as described
previously.10 Hepatocytes were rinsed twice and then
preincubated for 10 min at 37◦C with 0.6 mL of
warmed Hank’s balanced salt solution (HBSS) either
containing Ca2+ or not containing Ca2+ to maintain
or disrupt the tight junctions sealing bile canalicu-
lar networks, respectively. Subsequently, hepatocytes
were incubated with the test compound (1:M for
[3H]taurocholate and 10:M for the other compounds)
in standard HBSS for 10 min at 37◦C. After incu-
bation, the dosing solution was aspirated from the
cells, and uptake was stopped by washing the cells
three times with ice-cold standard HBSS. For radiola-
beled compound, cells were lysed with 0.5 mL of 0.5%
Triton X-100 in phosphate-buffered saline (Sigma-
Aldrich, St. Louis, Missouri). The samples were an-
alyzed for compound concentrations by liquid scintil-
lation counting. For other compounds, cells were lysed
with 0.3 mL of 90% (v/v) methanol containing 100 ng/
mL of rosuvastatin-d6 (internal standard) and soni-
cated for 30 s with a sonic dismembrator (model 100;
Thermo Fisher Scientific, Waltham, Massachusetts)
and then transferred to a 96-well centrifugation fil-
terplate (Corning Inc., Acton, Massachusetts). After
centrifugation (2095g × 20 min), the filtrates were
transferred to a 96-well plate and sealed for LC–MS/
MS analysis. Substrate accumulation was corrected
for nonspecific binding by using Matrigel-precoated
24-well plates without cells. Because of incompati-
bility of the protein assay with methanol, the average
protein concentration for standard HBSS or Ca2+-free
HBSS incubations in the same liver preparation was
used to normalize accumulation. Lysates were quan-
tified by the bicinchoninic acid protein assay (Pierce
Biotechnology, Inc., Rockford, Illinois) using bovine
serum albumin as the reference standard, and accu-
mulation was normalized to protein concentration.
LC–MS/MS Analysis
An Agilent 1100 HPLC system (Agilent Inc., Santa
Clara, California) connected to an Applied Biosys-
tems API 3000 triple quadrupole mass spectrometer
with an electrospray ion source (Foster City, Califor-
nia) was used for sample analysis. A total of 20:L
of sample was injected into the LC–MS/MS. The flow
rate of the mobile phases [aqueous phase, water with
0.1% formic acid (v/v) and 10 mM ammonium formate;
organic phase, acetonitrile with 0.1% formic acid (v/
v)] was 0.3 mL/min. Isocratic or gradient elution was
used to elute the various compounds from a Zorbax
ODS C18 (50 × 2.1 mm2, 3:m) column (Agilent Inc.).
Rosuvastatin-d6 was used as an internal standard.
The standard curve for each compound was individu-
ally established by using Matrigel-precoated 24-well
plates with hepatocytes.
Data Analysis
In vitro apparent CLb (CLb, app, in vitro;
mL*min−1*mg−1 of protein), based on compound
concentration in the medium, and in vitro intrinsic
CLb (CLb, int, in vitro; mL*min
−1*mg−1 of protein),
based on intracellular compound concentration in
SCRHs, were calculated using B-CLEAR R© technology
(Qualyst, Inc.) by the following equations9,10,60:
CLb, app, invitro
= accumulatationcells+bile − accumulatationcells
concentration(medium) × 10 min
(2)
CLb, app, invitro
= accumulatationcells+bile − accumulatationcells
(accumulatationcells/intracellular volume) × 10 min .
(3)
The concentration of compound in the medium
was defined as the initial substrate concentration
(1 or 10:M) in the incubation medium. Intracellu-
lar volume was assumed to be 5.2:L/mg protein.60
CLb, app, in vitro and CLb, int, in vitro (mL*min
−1*mg−1 of
protein) were scaled to kilograms of body weight
(CL′b, app and CL′b, int) assuming 200 mg protein/g rat
liver tissue and 40 g rat liver tissue/kg body weight.
The predicted in vivo CLb, app values were estimated
according to Eq. 4 given below, based on the well-
stirred model of hepatic disposition, assuming that
the red blood cell partitioning of test compounds was
minimal.
Invivo CLb,app = (Qp × fu × CL′b,app)
/ (Qp + fu × CL′b,app) (4)
where Qp represents the rat hepatic plasma flow rate
(40 mL*min−1*kg−1)8 and fu represents the unbound
fraction in rat plasma.
Average absolute fold error (AAFE)1 was used to
assess the prediction precision of various correction
approaches. AAFE was calculated as following:
AAFE = 101/n
∑∣∣∣∣log
(
predicted CL
observed CL
)∣∣∣∣ (5)
Data Set
Forty-one compounds, which were reported to un-
dergo biliary excretion, were randomly assigned to
a training set (n = 21) and a test set (n = 20). The
in vitro biliary excretion parameters of 21 compounds
in the training set were experimentally determined
from the SCRH model. The SCRH biliary excretion
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parameters of 20 compounds in the independent test
set, the values of fu in rat plasma and the in vivo
CLb values for the 41 compounds from the training
and test sets were all collected from the literature.
When in vivo CLb was not available in the literature,
it was calculated by the following equation: CLb =
CLtotal × % of dose as parent compound in bile. Com-
pounds in the training and test sets were divided into
low, moderate, and high CLb categories on the basis of
predicted or observed in vivo CLb values. Compounds
with an in vivo CLb of 30% (12 mL*min−1*kg−1) or
less of liver plasma flow were assigned to the low
CLb category, and compounds with an in vivo CLb
of 70% (28 mL*min−1*kg−1) or more of liver plasma
flow were assigned to the high CLb category. All other
compounds were assigned to the moderate CLb cat-
egory. Information regarding the major uptake and
efflux transporters of each compound was collected
from the literature (Tables 1 and 2) and UCSF-
FDA TransPortal (http://bts.ucsf.edu/fdatransportal/
index/).
RESULTS
Selection of Probe Substrates
The selection criteria for probe substrates in the train-
ing set included: rat in vivo CLb and rat plasma fu val-
ues available in literature; active hepatic uptake and/
or biliary excretion; and limited hepatic metabolism.
To ensure limited hepatic metabolism, the metabolic
stability of 18 compounds in the training set were as-
sessed in suspended rat cryopreserved hepatocytes.
As shown in Table S1, IVIVE from cryopreserved rat
hepatocyte incubation showed that all the 18 com-
pounds were metabolically stable. The other three
compounds (rosuvastatin, fexofenadine, and olmesar-
tan) in the training set have been previously reported
to be stable in rat liver microsome and hepatocyte
incubations.4,98
Determination of Universal Correction Factor
In vitro apparent CLb values based on compound
concentration in the medium were calculated using
Eq. 2 and scaled to kilograms of body weight (CL′b, app;
mL*min−1*kg−1) (Table 1 for training set and Table 2
for test set). The predicted CLb, app was obtained from
CL′b, app using Eq. 4 (Tables 1 and 2). A reasonable
linear correlation (R2 = 0.875) between the predicted
CLb, app and observed in vivo CLb was observed for 21
compounds in the training set (Fig. 1a), although the
observed in vivo CLb values were on average 10.2-fold
higher than the predicted values. Similarly, a linear
correlation (R2 = 0.746) between predicted CLb, app
and observed in vivo CLb was observed for 20 com-
pounds in the independent test set (Fig. 1b), and the
predicted CLb, app values were underestimated by an
average of 11.0-fold.
The slope (10.2) of the linear correlation equation
obtained from the training set was used as a univer-
sal correction factor to correct the underestimation
of CLb. The correction factor was applied to both the
training and test sets (Tables 1 and 2), and the cor-
rected CLb values were plotted against the observed
in vivo CLb for the training (squares) and test (trian-
gles) sets (Fig. 2). A total of seven out of 21 compounds
in the training set (highlighted in bold font in Table 1)
and seven out of 20 compounds in the test set (high-
lighted in bold font in Table 2) were outside the limit of
twofold error of the observed in vivo CLb. Noticeably,
the CLb values of candesartan and cefmetazole were
underpredicted, even after correction, by more than
30- and 20-fold, respectively. Poor prediction accuracy
of absolute CLb values was observed for compounds
with predicted CLb, app × 10.2 ≤ 3.5 mL*min−1*kg−1
in the training set (Fig. 2, solid squares; one out of
seven predictions within twofold error) and test set
(solid triangles; two out of seven predictions within
twofold error). By contrast, more accurate predic-
tions (13 out of 14 predictions within twofold error for
the training set and 11 out of 13 predictions within
twofold error for the test set) were achieved when the
predicted CLb, app × 10.2 was greater than 3.5 mL/
min/kg. Overall, when corrected by a universal factor
of 10.2, IVIVE from the SCRH model 10.2 provides ac-
ceptable predictability for compounds with moderate-
to-high CLb.
Although the absolute CLb values of compounds
with predicted CLb, app × 10.2 of 3.5 mL*min−1*kg−1
or less were inaccurately predicted, both predicted
and observed in vivo CLb consistently suggested low
biliary excretion. For all seven compounds with pre-
dicted CLb, app × 10.2 of 3.5 mL*min−1*kg−1 or less in
the test set (Table 2), both predicted and observed val-
ues consistently indicated that the compounds were
in the low CLb category (CLb < 12 mL*min−1*kg−1).
Similar results were found in the training set (Table
1). These observations suggest that the SCRH model
combined with a correction factor can be utilized to
predict whether an unknown compound has low, mod-
erate, or high CLb.
As a comparison, in vivo CLb was tentatively ex-
trapolated from CLb, int, in vitro, which is based on the
intracellular drug concentration in the SCRH model
(Eq. 3).99 CLb, int, in vitro (mL*min
−1*mg−1 of protein)
was scaled to in vivo CLb (mL*min−1*kg−1) using
physiological parameters; however, no linear corre-
lation between the predicted CLb and observed in
vivo CLb was observed in the training set (Table
S2 and Fig. S1). The linear regression R2 value was
0.235.
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Figure 1. Linear correlations between observed in vivo
CLb and predicted CLb, app in the (a) training set (n = 21)
and (b) test set (n = 20). Predicted CLb, app was based on
compound concentration in medium (Eq. 2) and obtained
from Eq. 4. Squares, compounds in the training set; trian-
gles, compounds in the test set.
Determination of Transporter-Specific Correction
Factors
As the variable (in vitro vs. in vivo) expression levels
of hepatic influx and efflux transporters in the SCRH
model lead to inaccuracies in predictions, transporter-
specific correction factors were introduced into IVIVE
to determine whether these corrections would im-
prove the model. The major influx and efflux trans-
porters involved in the active transport of substrates
are listed in Tables 1 and 2. The transporters in paren-
theses are minor transporters responsible for uptake
and efflux. Compounds in the training set were se-
lected for linear regression analysis by the following
criteria: predicted CLb, app × 10.2 was greater than
3.5 mL*min−1*kg−1; both uptake and efflux mecha-
nisms are known; and at least two compounds were
available in each group for linear regression. Hence,
seven compounds in the training set were divided
into an Oatps/Mrp2 group (n = 5) and a diffusion/P-
gp group (n = 2). Linear correlation analysis among
the five Oatps/Mrp2 substrates (Fig. 3a, squares) and
the two diffusion/P-gp substrates (Fig. 3b, squares)
in the training set gave Oatps/Mrp2-specific and dif-
fusion/P-gp-specific correction factors (11.8 and 8.0,
respectively).
Application of Transporter-Specific Correction Factors
to Test and Training Sets
The two transporter-specific correction factors were
appropriately applied to five Oatps/Mrp2 substrates
Figure 2. Plot between observed in vivo CLb and pre-
dicted CLb, app × 10.2 (n = 41). Dashed lines represent
the limit of twofold error of observed values. The dotted
line represents the boundary (predicted CLb, app × 10.2 =
3.5 mL*min−1*kg−1) between inaccurate predictions (left)
and accurate predictions (right). Squares, compounds in
the training set; triangles, compounds in the test set; solid
squares or triangles, compounds with predicted CLb, app ×
10.2 ≤ 3.5 mL*min−1*kg−1.
Figure 3. Linear correlations between observed in vivo
CLb and predicted CLb, app. (a) Oatps/Mrp2 substrates
(n = 5). (b) Diffusion/P-gp substrates (n = 2). Squares, com-
pounds in the training set; triangles, compounds in the test
set. The linear correlation analysis was based on compounds
in the training set.
and two diffusion/P-gp substrates in the test set
(Table 3; Fig. 3, triangles). The CLb values of
the other 13 compounds in the test set were not
corrected because either the corresponding correc-
tion factors were not available or the predicted
CLb, app × 10.2 was 3.5 mL*min−1*kg−1 or less. The
observed in vivo CLb values were plotted against the
predicted CLb values based on transporter-specific
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Figure 4. Plot between observed in vivo CLb and pre-
dicted CLb (n = 14) after correction with (a) transporter
activity-based factors and (b) a single universal factor
(10.2). Dotted lines represent the limits of 1.5-fold error
of observed values. Squares, compounds in the training set;
triangles, compounds in the test set; solid squares or trian-
gles, predictions outside 1.5-fold error.
corrections (Fig. 4a, triangles). All seven predictions
for the test set compounds were within 1.5-fold error
of the observed in vivo CLb. When the transporter-
specific correction factors were appropriately applied
to seven compounds in the training set (five Oatps/
Mrp2 substrates and two diffusion/P-gp substrates),
six predictions fell within 1.5-fold error, whereas the
predicted CLb of enalaprilat (7.35 mL*min−1*kg−1)
was more than twofold of the observed CLb (2.96 ±
0.32 mL*min−1*kg−1)18 (Fig. 4a, squares).
As a comparison, the general correction factor
(10.2) was applied to the seven test set compounds and
seven training set compounds (Table 3). The observed
in vivo CLb values were plotted against the predicted
CLb values based on the correction factor of 10.2
(Fig. 4b, triangles for the test set and squares for the
training set). The results show that the transporter-
specific corrections improve prediction precision com-
pared with the universal correction. For the seven
compounds in the test set, the AAFE of predictions
decreased from 1.24 (universal correction factor 10.2)
to 1.11 (transporter-specific correction factors). For
the seven compounds in the training set, the AAFE
of predictions decreased from 1.31 (universal correc-
tion factor 10.2) to 1.21 (transporter-specific correc-
tion factors).
DISCUSSION
Biliary excretion is an important elimination mecha-
nism of xenobiotics and their metabolites. Although
SCH models have been utilized to estimate human
and rat CLb for more than a decade,99,100 the ac-
curate prediction of CLb is still a challenging task.
For drugs that undergo similar uptake and efflux
mechanisms, such as angiotensin II receptor block-
ers, HMG-CoA reductase inhibitors, and $-lactam an-
tibiotics, the CLb values predicted by SCHs are lin-
early correlated with observed in vivo CLb.9,11,100,97
However, CLb can be underestimated by 10–100-fold
because of limited dynamic bile and blood flow and
time-dependent alterations in the protein concentra-
tion of influx and efflux transporters.3,4 To address
this underestimation, Li et al.4 incorporated ratios of
efflux transporter protein levels in rat liver to those in
SCRHs into IVIVE as correction factors. Similarly, in
the present study, compounds were divided into sub-
groups based on uptake and efflux mechanisms. We
utilized the ratio of the active transport activity in rat
liver and to that in SCRH as a transporter-specific cor-
rection factor for each subgroup. Transporter-based
correction factors were obtained by linear correlation
analysis between the observed in vivo CLb and pre-
dicted CLb, app of training set compounds that undergo
the same influx and efflux mechanisms. Compared
with correction factors based on the protein amount
of efflux transporters only, the transporter-based cor-
rection factors in this study address the variable ac-
tivities of both influx and efflux transporters in the
SCRH model. The predictability of the correction fac-
tors was examined using an independent test set in
which the in vitro and in vivo data were collected from
the literature. The results showed that both the pre-
diction accuracy and precision were improved by in-
corporating the transporter-based correction factors
into IVIVE.
In this study, a linear correlation between predicted
CLb, app from the SCRH model and in vivo CLb was ob-
served in both a training and an independent test set
(Figs. 1a and 1b), although different uptake and efflux
mechanisms were involved in the biliary excretion of
these compounds (Tables 1 and 2). The lower coeffi-
cient of determination in the literature-based test set
(R2 = 0.746) than in the training set (R2 = 0.875)
is likely because of interbatch and interlaboratory
variations. The underestimation of CLb, app between
the training set (10.2-fold) and the independent test
set (11.0-fold) was consistent, suggesting that the un-
derestimation of CLb can be corrected by an empir-
ical correction factor. Consistent with the previous
reports,11,60,101 normalization with fu in rat plasma in
Eq. 4 significantly improved the linear correlation be-
tween the predicted CLb, app and observed in vivo CLb
but caused further underestimation of CLb. When fu
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Table 3. Comparison of CLb Predictions for Seven Compounds in the Training Set and Seven Compounds in the Test Set Using
Transporter-Specific Corrections Versus a Universal Correction
Predicted CLb (mL*min−1*kg−1)
Compounds
Transporter-Based
Subgroup
Predicted CLb, app (Eq. 4)
(mL*min−1*kg−1)
With
Transporter-Based
Correctiona
With Universal
Correction
Factorb 10.2
Observed In Vivo
CLb
(mL*min−1*kg−1)
Training Set
Atorvastatin Oatps/Mrp2 (11.8) 0.546 6.43 5.56 6.2
Temocaprilat Oatps/Mrp2 (11.8) 2.72 32.1 27.8 34.4
Enalaprilat Oatps/Mrp2 (11.8) 0.624 7.35 6.36 2.96
Benazeprilat Oatps/Mrp2 (11.8) 1.65 19.5 16.9 20.2
Fexofenadine Oatps/Mrp2 (11.8) 1.28 15.1 13.0 11.4
Vincristine Diffusion/P-gp (8.0) 4.13 33.1 42.1 33.1
Colchicine Diffusion/P-gp (8.0) 1.15 9.19 11.7 9.05
AAFE of training set (n = 7) 1.21 1.31
Test Set
Pravastatin Oatps/Mrp2 (11.8) 1.99 23.4 20.3 27.9
Methotrexate Oatps/Mrp2 (11.8) 1.35 15.9 13.7 12.1
E217$G Oatps/Mrp2 (11.8) 2.92 34.4 29.7 32.1
Cefpiramide Oatps/Mrp2 (11.8) 0.462 5.44 4.71 5.47
ICG Oatps/Mrp2 (11.8) 2.37 27.9 24.2 32
Rhodamine123 Diffusion/P-gp (8.0) 2.26 18.1 23.1 18.3
Digoxin Diffusion/P-gp (8.0) 2.78 22.3 28.3 21
AAFE of test set (n = 7) 1.11 1.24
AAFE of both training set and test set (n = 14) 1.16 1.27
aA correction of 11.8 was applied to compounds in the Oatps/Mrp2 subgroup, and a correction of 8.0 was applied to compounds in the diffusion/P-gp
subgroup.
bA universal correction factor of 10.2 was used.
Predictions outside the 1.5-fold error of observed in vivo CLb are highlighted in bold.
AAFE, average absolute fold error; CLb, biliary clearance; CLb, app, apparent biliary clearances.
was not incorporated into Eq. 4, the predicted CLb was
closer to in vivo CLb but the correlation coefficient of
determination was much lower (data not shown).
The value of 3.5 mL/min/kg for predicted CLb, app ×
10.2 was found to be a cutoff level for accurate pre-
diction of CLb in the SCRH model. The CLb of com-
pounds with high CLb, app, in vitro and/or low plasma
protein binding are more likely to be accurately pre-
dicted by the SCRH model. For compounds with low
CLb, app, in vitro and/or high plasma protein binding,
CLb might be underestimated by up to 30-fold (e.g.,
candesartan) or overestimated by up to 14-fold (e.g.,
lomefloxacin), although both predicted and observed
CLb consistently suggested low biliary excretion for
these compounds (CLb < 12 mL*min−1*kg−1). The
poor predictions could be a result of many factors.
First, a measurement error in in vitro and in vivo
CLb may affect the prediction accuracy, especially for
compounds with low biliary excretion. Second, pre-
diction errors might be caused by variable trans-
porter activities in the SCRH model. For example,
decreased sinusoidal influx transporter activities in
SCRH might have caused the underprediction of CLb
of octreotide, cefoperazone, cephradine, and cefmeta-
zole. A previous report showed that CLb values of
cefoperazone and cefmetazole were consistently un-
derestimated by more than 10-fold, even though the
Mrp2 protein concentration ratio between rat liver
and SCRH was incorporated into IVIVE as a cor-
rection factor.4 On the contrary, increased or rela-
tively unchanged canalicular efflux transporter ac-
tivities likely resulted in the overprediction of CLb
for lomefloxacin, rifampicin, and dexamethasone, es-
pecially when the universal correction factor 10.2
was incorporated into IVIVE. Third, compounds with
high plasma protein binding, not surprisingly, exhibit
poor predictions of CLb. When fu is 0.01 or less (e.g.,
indomethacin, deferasirox, olmesartan, candesartan,
and valsartan), normalization with fu (Eq. 4) is ex-
pected to cause significant prediction errors because
of potential measurement errors in fu. Fourth, to
achieve good responses on LC–MS/MS, most com-
pounds, especially those with low hepatocyte uptake,
were incubated at 10:M in protein-free medium. For
high-protein-binding compounds, the free concentra-
tion in the medium was much higher than the plasma-
free drug concentrations in rats used for in vivo CLb
measurement. The high concentration in the medium
might partially saturate influx and/or efflux trans-
porters in SCRHs, especially for compounds with low
CLb, app, in vitro and a low Michaelis constant (Km), thus
resulting in underprediction of CLb (e.g., deferasirox,
olmesartan, candesartan, and valsartan). If a very
sensitive assay is available for compound quantita-
tion, the prediction errors caused by high protein
binding might be reduced by adding plasma protein
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to the incubation medium35 or preparing the dos-
ing solution in rat serum102 for which normalization
with fu is not required. It is noteworthy to mention
that the addition of serum proteins to incubation
medium did not remarkably change hepatocyte up-
take of some lipophilic compounds with very high pro-
tein binding.35 For these lipophilic compounds, serum
proteins in culture medium serve as a drug solubi-
lizer. The protein-bound drug might be transferred
to hepatocyte cell membranes during protein–hepa-
tocyte interaction, and the serum proteins facilitate
drug uptake. This observation might explain the un-
derestimation of CLb for very high-protein-binding
drugs such as olmesartan and candesartan in the
current study where fu correction was incorporated
(Eq. 4).
Most SCRH studies are designed to determine
CLb, app, in vitro on the basis of compound concentration
in medium (Eq. 2), and then the predicted CLb, app is
correlated with the observed in vivo CLb, app on the
basis of compound concentration in rat plasma. Re-
cently, Nakakariya et al.60 reported IVIVE between
CLb, int, in vitro and in vivo intrinsic CLb, which are
based on compound concentrations in hepatocytes in
the SCRH model (Eq. 3) and in liver tissue, respec-
tively. In the SCRH model, the expression levels of
sinusoidal influx transporters considerably decrease,
whereas the protein expression of canalicular efflux
transporters is relatively maintained during culture.
Theoretically, IVIVE from CLb, int, in vitro values that
reflect only canalicular efflux processes, should, there-
fore, be less susceptible to the variable expression of
influx transporters.60 Unfortunately, compound con-
centrations in rat liver were not available, and so in
vivo intrinsic CLb values were unable to be deter-
mined in the current study. We, therefore, tentatively
plotted the CLb extrapolated from CLb, int, in vitro and
the observed in vivo CLb. A very poor correlation be-
tween in vivo CLb, app and CLb, int, in vitro was observed
(Table S2 and Fig. S1). The CLb, int, in vitro only takes
into account the canalicular efflux of a compound.
However, in vivo CLb is a function of both the ba-
solateral uptake and canalicular efflux. Therefore, a
correlation would be expected only in cases where the
canalicular efflux was the rate-limiting step.
Two uptake and efflux mechanism-based factors
were obtained by linear correlation analysis between
predicted CLb, app and observed in vivo CLb. The
Oatps/Mrp2-specific factor (11.8) was higher than the
universal factor (10.2), which might be explained by
the decreased expression of Oatps in the SCRH model.
The low value of the diffusion/P-gp-specific factor (8.0)
was likely due to the unchanged or increased ex-
pression of P-gp in the SCRH model. Transporter
expression variability between batches of SCRHs
might limit the successful application of transporter-
based corrections. Previous transporter quantitation
studies7,8 consistently revealed that the changes in
transporter expression and activities were mainly de-
pendent on SCRH culture time. A dramatic decrease
or increase in transporter expression occurred during
0–72 h after cell seeding. On day 4 and day 5 after
cell seeding, further changes in transporter expres-
sion were relatively limited. In this study and the
studies in the literature, the incubation of compounds
with SCRHs was usually conducted on day 4 and day
5 after cell seeding, which might explain the compara-
ble transporter activities among SCRH models used
for the training set and test set compounds. Because
of the time-sensitive changes in transporter expres-
sion in the SCRH model, a consistent culture time is
highly recommended.
The transporter-based correction approach for CLb
predictions requires an understanding of the major
uptake and efflux mechanisms undergone by the drug
candidate, which are usually not available at the early
stage of drug development. In the absence of this in-
formation, the universal correction factor gave rea-
sonable CLb predictions when the predicted CLb was
greater than 3.5 mL/min/kg. For compounds with low
in vivo CLb, the SCRH model combined with the uni-
versal correction factor could not quantitatively esti-
mate absolute values of CLb, but it could qualitatively
assign compounds to low, moderate, and high CLb cat-
egories.
CONCLUSIONS
In this study, we demonstrated that both the univer-
sal correction factor and transporter-based correction
factors provide reasonable corrections of CLb, which
are usually underestimated by the SCRH model.
Transporter-based correction factors improved pre-
dictions compared with a universal correction fac-
tor. Considering the complicated hepatobiliary clear-
ance processes of hepatic uptake, sinusoidal efflux,
metabolism, and canalicular efflux, this transporter-
based corrected IVIVE method provides excellent pre-
dictions of rat CLb.
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